Q&A with Vadim Alexandre Head of Research at Northland Capital Partners

Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss ImmuPharma PLC (LON:IMM)

 

Q1: Now, we recently spoke about an AIM gem, ImmuPharma PLC, little did we know that they were about to release an update on their Phase III trials. Vadim, what were the highlights from that announcement?

A1: Yes, so it’s a good announcement, it gives us more granularity on the trial and everything is going quite well actually, the only small tweak is that they now expect the readout in Q1 2018 instead of basically end of 2017. This is minor delay, we’re talking about 2 months, it’s not really a delay it’s more to do with the structure of the trial, basically when you treat the last patient, there’s 200 patients recruited and now dosed as they announced today, you have to monitor them for 12 months after that initial dosing. So, I suspect they’ve probably dosed the last patient sometime earlier this month so technically that would push us into early 2018 but like I said it’s only a couple of months’ difference, it’s really insignificant.

More importantly though is that they’ve had no major side effects in the 200 patients that have been dosed and that’s a very big positive because what that means is essentially, there going to monitor them for 12 months obviously, you would expect if there’s going to be a major side effect it would occur early on, shortly after dosing. So, now that all 200 patients have been dosed and there are no major effects we could probably reliably say that the drug remains safe which is consistent with their Phase IIb data and all data to date. This is one of the benefits of Lupuzor over other treatments, that the downside, if you like, of other treatments is there are major side effects whereas Lupuzor so far has shown very little side effects so that’s another big positive from the results that were announced today. I guess the key point is now with even a higher degree of certainty we now know that all 200 patients have been dosed and we can expect them to complete monitoring in very early 2018 and then shortly thereafter we’ll expect a top line result for the trial.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Immupharma Plc

    Learning About Lupus

    May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system

    Immupharma Plc

    ImmuPharma Change of Registered Office Address

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL.

    Immupharma Plc

    ImmuPharma Change of AGM Venue

    ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, today announced that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19

    Immupharma Plc

    Lupus Latest Facts: Causes, Symptoms and Treatments

    Lupus is a relatively rare inflammatory disease. In the US 1.5 million are currently living with the condition. It is an autoimmune disease that can affect various organs including the skin, joints, kidneys, and brain. What

    Immupharma Plc

    Selena Gomez urges fans to join the fight against Lupus

    US singer Selena Gomez has urged her fans across the world to join the fight against Lupus, an autoimmune disease. The disease leads to the body’s immune system becoming hyperactive, attacking normal and healthy tissues. On

    Immupharma Plc

    Understanding Lupus

    Lupus is a chronic (long-term) disease that can cause inflammation and pain in any part of your body. It’s an autoimmune disease, which means that your immune system — the body system that usually fights infections

    Immupharma Plc

    What to know about COVID-19 and lupus

    Lupus is a chronic autoimmune condition in which the immune system attacks its own tissues. People with lupus are at higher risk of infections, and those with lupus who develop COVID-19 may be at higher risk

    Immupharma Plc

    Frequently asked questions: coronavirus (COVID-19) and lupus

    Our Health Educator Network—health-care professionals and lupus specialists who provide individualized answers—have seen their inquires triple in the last week. The following are questions they’ve been frequently asked and their answers. Should I wear a facemask?

    Immupharma Plc

    Are People with Lupus Protected Against COVID-19?

    There is no evidence that taking hydroxychloroquine (Plaquenil) is effective in preventing a person from contracting the coronavirus (COVID-19). People with lupus should follow the guidance of their doctor and the safety guidelines being issued by

    Immupharma Plc

    Dr Miriam Stoppard on Lupus

    Lupus isn’t that common but when it strikes it can be very ­serious, even life-threatening. The story of the singer and ­actress Selena Gomez is a case in point. All lupus sufferers will be grateful to her because